Abstract
Background: Gastro-oesophageal reflux disease (GORD) is extremely common, with at least 1 in 10 people in the general population reporting heartburn and acid regurgitation on a weekly basis. GORD can also be associated with a variety of atypical symptoms, including chest pain, chronic cough, and laryngopharyngeal symptoms. The causes of GORD are multifactorial, and the severity of symptoms is influenced by peripheral and central factors, including psychosocial stress and anxiety. Therefore, for a variety of reasons, no single investigation provides a definitive diagnosis, and standard treatment with acid suppressants is not always effective. Summary: This review introduces the Lyon Consensus, now in its second iteration, a classification system that provides a “conclusive” positive or negative diagnosis of GORD by integrating the results of endoscopy, ambulatory reflux monitoring, and high-resolution manometry. Different algorithms are applied to patients with high and low pre-test probability of a causal relationship between reflux episodes and patient symptoms. The results of these studies identify patients with “actionable” results that require escalation, revision, or discontinuation of GORD treatment. Guidance is provided on the range of conservative treatments available for GORD, including dietary and lifestyle advice, antacids and alginates, and drugs that suppress acid secretion. Key Messages: GORD is a common disorder; however, the causes of reflux and symptoms can be complex. As a result, the diagnosis can be missed, and management is sometimes challenging, especially for patients with atypical symptoms. The Lyon classification establishes a conclusive diagnosis of GORD, based on results of endoscopic and physiological investigation. Typical symptoms usually respond to empiric use of alginate-antacid preparations and acid suppression; however, the management of treatment refractory symptoms is tailored to the individual.
References
1.
El-Serag
HB
, Sweet
S
, Winchester
CC
, Dent
J
. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review
. Gut
. 2014
;63
(6
):871
–80
. 2.
GBD 2017 Gastro-oesophageal Reflux Disease Collaborators
. The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
. Lancet Gastroenterol Hepatol
. 2020
;5
(6
):561
–81
. 3.
Vakil
N
, van Zanten
SV
, Kahrilas
P
, Dent
J
, Jones
R
; Global Consensus Group
. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus
. Am J Gastroenterol
. 2006
;101
(8
):1900
–20
. quiz 1943. 4.
Kahrilas
PJ
, McColl
K
, Fox
M
, OʼRourke
L
, Sifrim
D
, Smout
AJPM
, et al. The acid pocket: a target for treatment in reflux disease
. Am J Gastroenterol
. 2013
;108
(7
):1058
–64
. 5.
Fox
M
, Forgacs
I
. Gastro-oesophageal reflux disease
. BMJ
. 2006
;332
(7533
):88
–93
. 6.
Gyawali
CP
, de Bortoli
N
, Clarke
J
, Marinelli
C
, Tolone
S
, Roman
S
, et al. Indications and interpretation of esophageal function testing
. Ann N Y Acad Sci
. 2018
;1434
(1
):239
–53
. 7.
Tack
J
, Pandolfino
JE
. Pathophysiology of gastroesophageal reflux disease
. Gastroenterology
. 2018
;154
(2
):277
–88
. 8.
Curcic
J
, Roy
S
, Schwizer
A
, Kaufman
E
, Forras-Kaufman
Z
, Menne
D
, et al. Abnormal structure and function of the esophagogastric junction and proximal stomach in gastroesophageal reflux disease
. Am J Gastroenterol
. 2014
;109
(5
):658
–67
. 9.
Pandolfino
JE
, Kwiatek
MA
, Ho
K
, Scherer
JR
, Kahrilas
PJ
. Unique features of esophagogastric junction pressure topography in hiatus hernia patients with dysphagia
. Surgery
. 2010
;147
(1
):57
–64
. 10.
Gyawali
CP
, Zerbib
F
, Bhatia
S
, Cisternas
D
, Coss-Adame
E
, Lazarescu
A
, et al. Chicago classification update (V4.0): technical review on diagnostic criteria for ineffective esophageal motility and absent contractility
. Neurogastroenterol Motil
. 2021
;33
(8
):e14134
. 11.
Daum
C
, Sweis
R
, Kaufman
E
, Fuellemann
A
, Anggiansah
A
, Fried
M
, et al. Failure to respond to physiologic challenge characterizes esophageal motility in erosive gastro-esophageal reflux disease
. Neurogastroenterol Motil
. 2011
;23
(6
):517
–e200
. 12.
Sanagapalli
S
, Emmanuel
A
, Leong
R
, Kerr
S
, Lovat
L
, Haidry
R
, et al. Impaired motility in Barrettʼs esophagus: a study using high-resolution manometry with physiologic challenge
. Neurogastroenterol Motil
. 2018
;30
(8
):e13330
. 13.
Dent
J
, El-Serag
HB
, Wallander
MA
, Johansson
S
. Epidemiology of gastro-oesophageal reflux disease: a systematic review
. Gut
. 2005
;54
(5
):710
–7
. 14.
Becher
A
, Dent
J
. Systematic review: ageing and gastro-oesophageal reflux disease symptoms, oesophageal function and reflux oesophagitis
. Aliment Pharmacol Ther
. 2011
;33
(4
):442
–54
. 15.
Lee
JD
, Anggiansah
A
, Anggiansah
R
, Young
A
, Wong
T
, Fox
M
. Effects of age on the gastroesophageal junction, esophageal motility, and reflux disease
. Clin Gastroenterol Hepatol
. 2007
;5
(12
):1392
–8
. 16.
El-Serag
HB
, Satia
JA
, Rabeneck
L
. Dietary intake and the risk of gastro-oesophageal reflux disease: a cross sectional study in volunteers
. Gut
. 2005
;54
(1
):11
–7
. 17.
Zheng
Z
, Nordenstedt
H
, Pedersen
NL
, Lagergren
J
, Ye
W
. Lifestyle factors and risk for symptomatic gastroesophageal reflux in monozygotic twins
. Gastroenterology
. 2007
;132
(1
):87
–95
. 18.
Lagergren
J
. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk
. Gut
. 2005
;54
(Suppl 1
):i1
–5
. 19.
Pandolfino
JE
, El-Serag
HB
, Zhang
Q
, Shah
N
, Ghosh
SK
, Kahrilas
PJ
. Obesity: a challenge to esophagogastric junction integrity
. Gastroenterology
. 2006
;130
(3
):639
–49
. 20.
El-Serag
HB
, Ergun
GA
, Pandolfino
J
, Fitzgerald
S
, Tran
T
, Kramer
JR
. Obesity increases oesophageal acid exposure
. Gut
. 2007
;56
(6
):749
–55
. 21.
Anggiansah
R
, Sweis
R
, Anggiansah
A
, Wong
T
, Cooper
D
, Fox
M
. The effects of obesity on oesophageal function, acid exposure and the symptoms of gastro-oesophageal reflux disease
. Aliment Pharmacol Ther
. 2013
;37
(5
):555
–63
. 22.
Kessing
BF
, Bredenoord
AJ
, Saleh
CMG
, Smout
AJPM
. Effects of anxiety and depression in patients with gastroesophageal reflux disease
. Clin Gastroenterol Hepatol
. 2015
;13
(6
):1089
–95.e1
. 23.
Fox
M
, Schwizer
W
. Making sense of oesophageal contents
. Gut
. 2008
;57
(4
):435
–8
. 24.
Wong
M-W
, Liu
T-T
, Yi
C-H
, Lei
W-Y
, Hung
J-S
, Cock
C
, et al. Oesophageal hypervigilance and visceral anxiety relate to reflux symptom severity and psychological distress but not to acid reflux parameters
. Aliment Pharmacol Ther
. 2021
;54
(7
):923
–30
. 25.
Sawada
A
, Guzman
M
, Nikaki
K
, Sonmez
S
, Yazaki
E
, Aziz
Q
, et al. Identification of different phenotypes of esophageal reflux hypersensitivity and implications for treatment
. Clin Gastroenterol Hepatol
. 2021
;19
(4
):690
–8.e2
. 26.
Mainie
I
, Tutuian
R
, Shay
S
, Vela
M
, Zhang
X
, Sifrim
D
, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring
. Gut
. 2006
;55
(10
):1398
–402
. 27.
Gyawali
CP
, Kahrilas
PJ
, Savarino
E
, Zerbib
F
, Mion
F
, Smout
AJPM
, et al. Modern diagnosis of GERD: the Lyon consensus
. Gut
. 2018
;67
(7
):1351
–62
. 28.
Bredenoord
AJ
, Pandolfino
JE
, Smout
AJPM
. Gastro-oesophageal reflux disease
. Lancet
. 2013
;381
(9881
):1933
–42
. 29.
Ronkainen
J
, Aro
P
, Storskrubb
T
, Johansson
S-E
, Lind
T
, Bolling-Sternevald
E
, et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report
. Scand J Gastroenterol
. 2005
;40
(3
):275
–85
. 30.
Rusu
RI
, Fox
MR
, Tucker
E
, Zeki
S
, Dunn
JM
, Jafari
J
, et al. Validation of the Lyon classification for GORD diagnosis: acid exposure time assessed by prolonged wireless pH monitoring in healthy controls and patients with erosive oesophagitis
. Gut
. 2021
;70
(12
):2230
–7
. 31.
Kessing
BF
, Bredenoord
AJ
, Smout
AJPM
. Erroneous diagnosis of gastroesophageal reflux disease in achalasia
. Clin Gastroenterol Hepatol
. 2011
;9
(12
):1020
–4
. 32.
Tucker
E
, Knowles
K
, Wright
J
, Fox
MR
. Rumination variations: aetiology and classification of abnormal behavioural responses to digestive symptoms based on high-resolution manometry studies
. Aliment Pharmacol Ther
. 2013
;37
(2
):263
–74
. 33.
Yadlapati
R
, Tye
M
, Roman
S
, Kahrilas
PJ
, Ritter
K
, Pandolfino
JE
. Postprandial high-resolution impedance manometry identifies mechanisms of nonresponse to proton pump inhibitors
. Clin Gastroenterol Hepatol
. 2018
;16
(2
):211
–8.e1
. 34.
Rengarajan
A
, Bolkhir
A
, Gor
P
, Wang
D
, Munigala
S
, Gyawali
CP
. Esophagogastric junction and esophageal body contraction metrics on high-resolution manometry predict esophageal acid burden
. Neurogastroenterol Motil
. 2018
;30
(5
):e13267
. 35.
Vela
MF
, Camacho-Lobato
L
, Srinivasan
R
, Tutuian
R
, Katz
PO
, Castell
DO
. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole
. Gastroenterology
. 2001
;120
(7
):1599
–606
. 36.
Frazzoni
M
, Savarino
E
, de Bortoli
N
, Martinucci
I
, Furnari
M
, Frazzoni
L
, et al. Analyses of the post-reflux swallow-induced peristaltic wave index and nocturnal baseline impedance parameters increase the diagnostic yield of impedance-pH monitoring of patients with reflux disease
. Clin Gastroenterol Hepatol
. 2016
;14
(1
):40
–6
. 37.
Hasak
S
, Yadlapati
R
, Altayar
O
, Sweis
R
, Tucker
E
, Knowles
K
, et al. Prolonged wireless pH monitoring in patients with persistent reflux symptoms despite proton pump inhibitor therapy
. Clin Gastroenterol Hepatol
. 2020
;18
(13
):2912
–9
. 38.
Sweis
R
, Fox
M
, Anggiansah
R
, Anggiansah
A
, Basavaraju
K
, Canavan
R
, et al. Patient acceptance and clinical impact of Bravo monitoring in patients with previous failed catheter-based studies
. Aliment Pharmacol Ther
. 2009
;29
(6
):669
–76
. 39.
Gyawali
CP
, Yadlapati
R
, Fass
R
, Katzka
D
, Pandolfino
J
, Savarino
E
, et al. Updates to the modern diagnosis of GERD: Lyon consensus 2.0
. Gut
. 2024
;73
(2
):361
–71
. 40.
Gyawali
CP
, Tutuian
R
, Zerbib
F
, Rogers
BD
, Frazzoni
M
, Roman
S
, et al. Value of pH impedance monitoring while on twice-daily proton pump inhibitor therapy to identify need for escalation of reflux management
. Gastroenterology
. 2021
;161
(5
):1412
–22
. 41.
Yadlapati
R
, Gyawali
CP
, Masihi
M
, Carlson
DA
, Kahrilas
PJ
, Nix
BD
, et al. Optimal wireless reflux monitoring metrics to predict discontinuation of proton pump inhibitor therapy
. Am J Gastroenterol
. 2022
;117
(10
):1573
–82
. 42.
Campos
GMR
, Peters
JH
, DeMeester
TR
, Oberg
S
, Crookes
PF
, Tan
S
, et al. Multivariate analysis of factors predicting outcome after laparoscopic Nissen fundoplication
. J Gastrointest Surg
. 1999
;3
(3
):292
–300
. 43.
Spechler
SJ
, Hunter
JG
, Jones
KM
, Lee
R
, Smith
BR
, Mashimo
H
, et al. Randomized trial of medical versus surgical treatment for refractory heartburn
. N Engl J Med
. 2019
;381
(16
):1513
–23
. 44.
Wildi
SM
, Tutuian
R
, Castell
DO
. The influence of rapid food intake on postprandial reflux: studies in healthy volunteers
. Am J Gastroenterol
. 2004
;99
(9
):1645
–51
. 45.
Feldman
M
, Barnett
C
. Relationships between the acidity and osmolality of popular beverages and reported postprandial heartburn
. Gastroenterology
. 1995
;108
(1
):125
–31
. 46.
Pehl
C
, Waizenhoefer
A
, Wendl
B
, Schmidt
T
, Schepp
W
, Pfeiffer
A
. Effect of low and high fat meals on lower esophageal sphincter motility and gastroesophageal reflux in healthy subjects
. Am J Gastroenterol
. 1999
;94
(5
):1192
–6
. 47.
Nebel
OT
, Fornes
MF
, Castell
DO
. Symptomatic gastroesophageal reflux: incidence and precipitating factors
. Am J Dig Dis
. 1976
;21
(11
):953
–6
. 48.
Murphy
DW
, Castell
DO
. Chocolate and heartburn: evidence of increased esophageal acid exposure after chocolate ingestion
. Am J Gastroenterol
. 1988
;83
(6
):633
–6
.49.
Martin
Z
, Spry
G
, Hoult
J
, Maimone
IR
, Tang
X
, Crichton
M
, et al. What is the efficacy of dietary, nutraceutical, and probiotic interventions for the management of gastroesophageal reflux disease symptoms? A systematic literature review and meta-analysis
. Clin Nutr ESPEN
. 2022
;52
:340
–52
. 50.
Fox
M
, Barr
C
, Nolan
S
, Lomer
M
, Anggiansah
A
, Wong
T
. The effects of dietary fat and calorie density on esophageal acid exposure and reflux symptoms
. Clin Gastroenterol Hepatol
. 2007
;5
(4
):439
–44
. 51.
Simrén
M
, Abrahamsson
H
, Björnsson
ES
. An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome
. Gut
. 2001
;48
(1
):20
–7
. 52.
Feinle
C
, Rades
T
, Otto
B
, Fried
M
. Fat digestion modulates gastrointestinal sensations induced by gastric distention and duodenal lipid in humans
. Gastroenterology
. 2001
;120
(5
):1100
–7
. 53.
Gu
C
, Olszewski
T
, King
KL
, Vaezi
MF
, Niswender
KD
, Silver
HJ
. The effects of modifying amount and type of dietary carbohydrate on esophageal acid exposure time and esophageal reflux symptoms: a randomized controlled trial
. Am J Gastroenterol
. 2022
;117
(10
):1655
–67
. 54.
Wu
K-L
, Kuo
C-M
, Yao
C-C
, Tai
W-C
, Chuah
S-K
, Lim
C-S
, et al. The effect of dietary carbohydrate on gastroesophageal reflux disease
. J Formos Med Assoc
. 2018
;117
(11
):973
–8
. 55.
Pointer
SD
, Rickstrew
J
, Slaughter
JC
, Vaezi
MF
, Silver
HJ
. Dietary carbohydrate intake, insulin resistance and gastro-oesophageal reflux disease: a pilot study in European- and African-American obese women
. Aliment Pharmacol Ther
. 2016
;44
(9
):976
–88
. 56.
Taylors
IL
, Byrne
WJ
, Christie
DL
, Ament
ME
, Walsh
JH
. Effect of individual l-amino acids on gastric acid secretion and serum gastrin and pancreatic polypeptide release in humans
. Gastroenterology
. 1982
;83
(1
):273
–8
. 57.
Pohl
D
, Fox
M
, Fried
M
, Göke
B
, Prinz
C
, Mönnikes
H
, et al. Do we need gastric acid
. Digestion
. 2008
;77
(3–4
):184
–97
. 58.
McColl
KEL
. When saliva meets acid: chemical warfare at the oesophagogastric junction
. Gut
. 2005
;54
(1
):1
–3
. 59.
Manning
JJ
, Wirz
AA
, McColl
KEL
. Nitrogenous chemicals generated from acidification of saliva influence transient lower oesophageal sphincter relaxations
. Scand J Gastroenterol
. 2007
;42
(12
):1413
–21
. 60.
Morozov
S
, Isakov
V
, Konovalova
M
. Fiber-enriched diet helps to control symptoms and improves esophageal motility in patients with non-erosive gastroesophageal reflux disease
. World J Gastroenterol
. 2018
;24
(21
):2291
–9
. 61.
Piche
T
, des Varannes
SB
, Sacher-Huvelin
S
, Holst
JJ
, Cuber
JC
, Galmiche
JP
. Colonic fermentation influences lower esophageal sphincter function in gastroesophageal reflux disease
. Gastroenterology
. 2003
;124
(4
):894
–902
. 62.
Triadafilopoulos
G
, Korzilius
JW
, Zikos
T
, Sonu
I
, Fernandez-Becker
NQ
, Nguyen
L
, et al. Ninety-six hour wireless esophageal pH study in patients with GERD shows that restrictive diet reduces esophageal acid exposure
. Dig Dis Sci
. 2020
;65
(8
):2331
–44
. 63.
Moazzez
R
, Bartlett
D
, Anggiansah
A
. The effect of chewing sugar-free gum on gastro-esophageal reflux
. J Dent Res
. 2005
;84
(11
):1062
–5
. 64.
Piesman
M
, Hwang
I
, Maydonovitch
C
, Wong
RKH
. Nocturnal reflux episodes following the administration of a standardized meal. Does timing matter
. Am J Gastroenterol
. 2007
;102
(10
):2128
–34
. 65.
Hamilton
JW
, Boisen
RJ
, Yamamoto
DT
, Wagner
JL
, Reichelderfer
M
. Sleeping on a wedge diminishes exposure of the esophagus to refluxed acid
. Dig Dis Sci
. 1988
;33
(5
):518
–22
. 66.
Ness-Jensen
E
, Hveem
K
, El-Serag
H
, Lagergren
J
. Lifestyle intervention in gastroesophageal reflux disease
. Clin Gastroenterol Hepatol
. 2016
;14
(2
):175
–82.e1–3
. 67.
Schoeman
MN
, Tippett
MD
, Akkermans
LM
, Dent
J
, Holloway
RH
. Mechanisms of gastroesophageal reflux in ambulant healthy human subjects
. Gastroenterology
. 1995
;108
(1
):83
–91
. 68.
van Herwaarden
MA
, Katzka
DA
, Smout
AJPM
, Samsom
M
, Gideon
M
, Castell
DO
. Effect of different recumbent positions on postprandial gastroesophageal reflux in normal subjects
. Am J Gastroenterol
. 2000
;95
(10
):2731
–6
. 69.
Schuitenmaker
JM
, van Dijk
M
, Oude Nijhuis
RAB
, Smout
AJPM
, Bredenoord
AJ
. Associations between sleep position and nocturnal gastroesophageal reflux: a study using concurrent monitoring of sleep position and esophageal pH and impedance
. Am J Gastroenterol
. 2022
;117
(2
):346
–51
. 70.
Schuitenmaker
JM
, Kuipers
T
, Oude Nijhuis
RAB
, Schijven
MP
, Smout
AJPM
, Fockens
P
, et al. Sleep positional therapy for nocturnal gastroesophageal reflux: a double-blind, randomized, sham-controlled trial
. Clin Gastroenterol Hepatol
. 2022
;20
(12
):2753
–62.e2
. 71.
El-Serag
H
. The association between obesity and GERD: a review of the epidemiological evidence
. Dig Dis Sci
. 2008
;53
(9
):2307
–12
. 72.
El-Serag
HB
, Graham
DY
, Satia
JA
, Rabeneck
L
. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis
. Am J Gastroenterol
. 2005
;100
(6
):1243
–50
. 73.
Ayazi
S
, Hagen
JA
, Chan
LS
, DeMeester
SR
, Lin
MW
, Ayazi
A
, et al. Obesity and gastroesophageal reflux: quantifying the association between body mass index, esophageal acid exposure, and lower esophageal sphincter status in a large series of patients with reflux symptoms
. J Gastrointest Surg
. 2009
;13
(8
):1440
–7
. 74.
Jacobson
BC
, Somers
SC
, Fuchs
CS
, Kelly
CP
, Camargo
CA
Jr. Body-mass index and symptoms of gastroesophageal reflux in women
. N Engl J Med
. 2006
;354
(22
):2340
–8
. 75.
Mathus-Vliegen
LM
, Tytgat
GN
. Twenty-four-hour pH measurements in morbid obesity: effects of massive overweight, weight loss and gastric distension
. Eur J Gastroenterol Hepatol
. 1996
;8
(7
):635
–40
.76.
Fraser-Moodie
CA
, Norton
B
, Gornall
C
, Magnago
S
, Weale
AR
, Holmes
GKT
. Weight loss has an independent beneficial effect on symptoms of gastro-oesophageal reflux in patients who are overweight
. Scand J Gastroenterol
. 1999
;34
(4
):337
–40
. 77.
Park
S-K
, Lee
T
, Yang
H-J
, Park
JH
, Sohn
CI
, Ryu
S
, et al. Weight loss and waist reduction is associated with improvement in gastroesophageal disease reflux symptoms: a longitudinal study of 15 295 subjects undergoing health checkups
. Neurogastroenterol Motil
. 2017
;29
(5
):e13009
. 78.
Singh
M
, Lee
J
, Gupta
N
, Gaddam
S
, Smith
BK
, Wani
SB
, et al. Weight loss can lead to resolution of gastroesophageal reflux disease symptoms: a prospective intervention trial
. Obesity
. 2013
;21
(2
):284
–90
. 79.
Mathus-Vliegen
EM
. [Nutrition and health--ideal body weight for the obese unrealistic; health benefit by moderate sustained weight loss]
. Ned Tijdschr Geneeskd
. 2003
;147
(24
):1168
–72
.80.
Mehta
RS
, Nguyen
LH
, Ma
W
, Staller
K
, Song
M
, Chan
AT
. Association of diet and lifestyle with the risk of gastroesophageal reflux disease symptoms in US women
. JAMA Intern Med
. 2021
;181
(4
):552
–4
. 81.
Gyawali
CP
, Fass
R
. Management of gastroesophageal reflux disease
. Gastroenterology
. 2018
;154
(2
):302
–18
. 82.
Koop
H
, Fuchs
KH
, Labenz
J
, Lynen Jansen
P
, Messmann
H
, Miehlke
S
, et al. S2k-leitlinie: gastroösophageale refluxkrankkheit unter federführung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs-und Stoffwechselkrankheiten (DGVS)
. Z Gastroenterol
. 2014
;52
(11
):1299
–346
. 83.
Jankowski
JAZ
, de Caestecker
J
, Love
SB
, Reilly
G
, Watson
P
, Sanders
S
, et al. Esomeprazole and aspirin in Barrettʼs oesophagus (AspECT): a randomised factorial trial
. Lancet
. 2018
;392
(10145
):400
–8
. 84.
Yadlapati
R
, Gyawali
CP
, Pandolfino
JE
; CGIT GERD Consensus Conference Participants
. AGA clinical practice update on the personalized approach to the evaluation and management of GERD: expert review
. Clin Gastroenterol Hepatol
. 2022
;20
(5
):984
–94.e1
. 85.
Vaezi
MF
, Yang
Y-X
, Howden
CW
. Complications of proton pump inhibitor therapy
. Gastroenterology
. 2017
;153
(1
):35
–48
. 86.
Moayyedi
P
, Eikelboom
JW
, Bosch
J
, Connolly
SJ
, Dyal
L
, Shestakovska
O
, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin
. Gastroenterology
. 2019
;157
(3
):682
–91.e2
. 87.
Sweis
R
, Kaufman
E
, Anggiansah
A
, Wong
T
, Dettmar
P
, Fried
M
, et al. Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients
. Aliment Pharmacol Ther
. 2013
;37
(11
):1093
–102
. 88.
Rohof
WO
, Bennink
RJ
, Smout
AJPM
, Thomas
E
, Boeckxstaens
GE
. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease
. Clin Gastroenterol Hepatol
. 2013
;11
(12
):1585
–91
. 89.
De Ruigh
A
, Roman
S
, Chen
J
, Pandolfino
JE
, Kahrilas
PJ
. Gaviscon double action liquid (antacid and alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study
. Aliment Pharmacol Ther
. 2014
;40
(5
):531
–7
. 90.
Savarino
E
, de Bortoli
N
, Zentilin
P
, Martinucci
I
, Bruzzone
L
, Furnari
M
, et al. Alginate controls heartburn in patients with erosive and nonerosive reflux disease
. World J Gastroenterol
. 2012
;18
(32
):4371
–8
. 91.
Thomas
E
, Wade
A
, Crawford
G
, Jenner
B
, Levinson
N
, Wilkinson
J
. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease
. Aliment Pharmacol Ther
. 2014
;39
(6
):595
–602
. 92.
Deraman
MA
, Abdul Hafidz
MI
, Lawenko
RM
, Ma
ZF
, Wong
MS
, Coyle
C
, et al. Randomised clinical trial: the effectiveness of Gaviscon Advance vs non-alginate antacid in suppression of acid pocket and post-prandial reflux in obese individuals after late-night supper
. Aliment Pharmacol Ther
. 2020
;51
(11
):1014
–21
. 93.
Pouchain
D
, Bigard
M-A
, Liard
F
, Childs
M
, Decaudin
A
, McVey
D
. Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial
. BMC Gastroenterol
. 2012
;12
:18
. 94.
McGlashan
JA
, Johnstone
LM
, Sykes
J
, Strugala
V
, Dettmar
PW
. The value of a liquid alginate suspension (Gaviscon Advance) in the management of laryngopharyngeal reflux
. Eur Arch Oto-Rhino-Laryngol
. 2009
;266
(2
):243
–51
. 95.
Reimer
C
, Bytzer
P
. Editorial: alginates for inadequate response to a proton pump inhibitor in gastro-oesophageal reflux disease-authorsʼ reply
. Aliment Pharmacol Ther
. 2016
;43
(10
):1104
. 96.
Labenz
J
, Koop
H
. Gastroösophageale Refluxkrankheit–was tun, wenn PPI nicht ausreichend wirksam, verträglich oder erwünscht sind
. Dtsch Med Wochenschr
. 2017
;142
(05
):356
–66
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
